Kidney Disease
Return to Library
|
Free Kidney Disease Articles |
|
|
|
|
Studies by F. Guebreegziabher and co-authors describe new findings in dialysis
2009 AUG 24 - (NewsRx.com) -- According to recent research from Lyon, France, "Resistance to GH and IGF-I is a significant complication of severe chronic kidney disease, which contributes to muscle wasting. Pharmacological doses of recombinant human (rh) GH or rhIGF-I have been proposed to treat this catabolic condition." "This study was undertaken to examine the potential additive anabolic effects of rhGH + rhIGF-I compared with rhIGF-I. We studied eight well-nourished hemodialysis patients in a random crossover design and compared the metabolic effects of a 3-d administration of moderate dose of rhIGF-I (40 mu g/kg per 12h) with an association of rhIGF-I + rhGH (50 mu g/kg/d). Leucine kinetics, plasma amino acids (AAs), serum insulin, and IGF binding proteins (IGFBP)-1 and -3 were measured. The net protein balance was not affected by rhIGF-I alone, whereas serum insulin and IGFBP-3 decreased (P < 0.05) and IGFBP-1 increased (P < 0.01). With the combination rhGH + rhIGF-I, an increase of IGFBP-3 (P < 0.01) and insulin (P < 0.01) as well as a decrease of IGFBP-1 (P < 0.01) occurred. Plasma essential AAs (P < 0.01) as well as the essential to nonessential AA ratio (P < 0.001) decreased. Whole-body protein net balance increased significantly (P < 0.05) with a 22% decrease in leucine oxidation and a 15% increase in nonoxidative leucine disposal," wrote F. Guebreegziabher and colleagues. The researchers concluded: "In dialysis patients, rhIGF-I administration at a moderate dose has no protein metabolic effect, but the association with a moderate dose of rhGH is followed by a significant anabolic response. (J Clin Endocrinol Metab 94: 2299-2305, 2009)." Guebreegziabher and colleagues published their study in the Journal of Clinical Endocrinology & Metabolism (Short-Term Administration of a Combination of Recombinant Growth Hormone and Insulin-Like Growth Factor-I Induces Anabolism in Maintenance Hemodialysis. Journal of Clinical Endocrinology & Metabolism, 2009;94(7):2299-2305). For additional information, contact F. Guebreegziabher, Hopital Edouard Herriot, Dept. of Nephrology, F-69437 Lyon 03, France. Publisher contact information for the Journal of Clinical Endocrinology & Metabolism is: Endocrine Society, 8401 Connecticut Avenue, Suite 900, Chevy Chase, MD 20815-5817, USA. Keywords: France, Lyon, Amino Acids, Clinical Endocrinology, Drugs, Hemodialysis, Hormones, IGF I, Kidney Disease, Medical Device, Metabolism, Pharmaceuticals, Pharmacological, Recombinant Growth Hormone, Renal Dialysis, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
